ZURICH – Swiss innovator HeiQ has undertaken new tests of its Viroblock NPJO3 antiviral textile treatment, concluding that it’s capable of reducing the virus by 99.99 per cent.
Conducted by the Peter Doherty Institute for Infection and Immunity in Melbourne, HeiQ’s technology – which is a combination of vesicle and silver technologies that work by binding to viral sulfur groups and depleting their membranes – has been found an effective killer of the strain of coronavirus that’s gripped the world.
“The confirmation of antiviral activity of HeiQ Viroblock against SARS-CoV-2 is an important milestone,” said HeiQ CEO, Carlo Centonze. “This data forms part of our ongoing efforts to help provide textiles with greater levels of protection against viruses and contribute to efforts towards mitigation of the global pandemic.”
